AB
ABSI.US Absci Corp
- Market cap
- USD 1.57B
- P/E
- -
- P/B
- 7.03x
- ROE
- -51.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ABSI.US undervalued?
Graham numberThe Graham number of Absci Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Absci Corp fundamental analysis
No fundamental analysis for Absci Corp yet.
Absci Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Absci Corp
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporat…
Full company profileAbsci Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Absci Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 2.06M | 4.78M | 4.78M | 5.75M | 5.72M | 4.53M | 2.80M | 1.07M |
| Gross Profit | 2.06M | -6.67M | -39.8M | -53.2M | -41.8M | -57.9M | -8.94M | -4.39M |
| Operating Income | -6.27M | -13.3M | -75.2M | -107M | -116M | -109M | -125M | -130M |
| EBITDA | -5.83M | -12.6M | -67.7M | -91.3M | -79.7M | -94.1M | -103M | -115M |
| Net Income | -6.58M | -14.4M | -101M | -105M | -111M | -103M | -115M | -126M |
| EPS | -0.07 | -0.16 | -1.09 | -1.15 | -1.20 | -0.94 | -0.84 | -0.80 |
| Balance Sheet | ||||||||
| Total Assets | 19.5M | 88.6M | 426M | 321M | 217M | 214M | 216M | 269M |
| Total Liabilities | 60.6M | 21.6M | 60.1M | 46.6M | 41.1M | 34.5M | 26.8M | 22.8M |
| Shareholders' Equity | -41.2M | 67.0M | 366M | 274M | 176M | 179M | 189M | 246M |
| Cash & Short-term Investments | 13.1M | 69.9M | 253M | 164M | 97.7M | 112M | 144M | 201M |
| Total Debt | 6.02M | 14.5M | 20.0M | 23.0M | 15.9M | 10.1M | 5.30M | 3.68M |
| Cash Flow | ||||||||
| Operating Cash Flow | -6.03M | -11.0M | -60.6M | -81.3M | -64.6M | -72.4M | -92.9M | -108M |
| Capital Expenditure | 1.10M | 2.18M | 38.0M | 16.2M | 860K | 404K | 1.11M | 62.0K |
| Free Cash Flow | -7.13M | -13.2M | -98.6M | -97.5M | -65.5M | -72.8M | -94.0M | -108M |
| Ratios | ||||||||
| ROE | - | -21.4% | -27.6% | -38.2% | -62.8% | -57.6% | -60.8% | -51.0% |
| ROA | -33.8% | -16.2% | -23.7% | -32.7% | -50.9% | -48.3% | -53.3% | -46.7% |
| Net Profit Margin | -319.6% | -300.3% | -2,111.3% | -1,825.4% | -1,933.6% | -2,274.1% | -4,113.7% | -11,784.1% |
| Debt to Equity | - | 0.22x | 0.05x | 0.08x | 0.09x | 0.06x | 0.03x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Absci Corp dividends
Absci Corp has not paid dividends in the last 7 fiscal years.
Who owns Absci Corp
- Insiders 11.78%
- Institutions 88.22%
- Public & others 0.00%
- Shares outstanding 172M
- Free float 165M
Top funds holding ABSI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| ARK Genomic Revolution ETF | 11.0M | 6.40% | +0.58% | Oct 2026 |
| Fidelity Growth Company Fund | 8.02M | 4.68% | +1.51% | Aug 2026 |
| State Street® SPDR® S&P® Biotech ETF | 5.31M | 3.09% | +2.69% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 5.08M | 2.96% | +13.85% | Sep 2026 |
| iShares Russell 2000 ETF | 3.83M | 2.23% | 0.00% | Oct 2026 |
| Fidelity Growth Company K6 | 2.50M | 1.46% | +1.37% | Aug 2026 |
| Fidelity Series Growth Company | 2.17M | 1.26% | +1.37% | Aug 2026 |
| ARK Venture D | 1.63M | 0.95% | -46.05% | Jul 2026 |
| Fidelity Select Biotechnology | 1.57M | 0.92% | -0.33% | Aug 2026 |
| Fidelity Small Cap Index | 1.51M | 0.88% | 0.00% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 1.18M | 0.69% | -0.38% | Oct 2026 |
| iShares Biotechnology ETF | 1.15M | 0.67% | -0.19% | Oct 2026 |
| Nuveen Quant Small Cap Equity R6 | 975K | 0.57% | 0.00% | Aug 2026 |
| Columbia Acorn Inst | 878K | 0.51% | -0.38% | Sep 2026 |
| Vanguard Russell 2000 ETF | 874K | 0.51% | +9.89% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 855K | 0.50% | +0.24% | Oct 2026 |
| Fidelity Extended Market Index | 743K | 0.43% | +11.16% | Sep 2026 |
| Alger Small Cap Growth A | 679K | 0.40% | +5.39% | Aug 2026 |
| ARK Genomic Revolution ETF A USD Acc | 577K | 0.34% | 0.00% | Oct 2026 |
| Bridge Builder Small Cap Fund | 558K | 0.33% | +78.86% | Oct 2026 |
Top institutions holding ABSI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 25.4M | 14.81% | +12.68% | Jun 2026 |
| ARK Investment Management LLC | 12.9M | 7.53% | -5.83% | Jun 2026 |
| BlackRock Inc | 12.2M | 7.09% | +8.18% | Jun 2026 |
| State Street Corp | 8.10M | 4.72% | +10.55% | Jun 2026 |
| Ameriprise Financial Inc | 6.99M | 4.07% | +119.86% | Jun 2026 |
| Redmile Group, LLC | 6.74M | 3.93% | -18.34% | Jun 2026 |
| Vanguard Capital Management, LLC | 6.12M | 3.57% | +4.01% | Jun 2026 |
| Advanced Micro Devices Inc | 5.71M | 3.33% | 0.00% | Jun 2026 |
| Adage Capital Partners Gp LLC | 5.70M | 3.32% | 0.00% | Jun 2026 |
| Two Sigma Investments LLC | 5.49M | 3.20% | +89.51% | Jun 2026 |
| D. E. Shaw & Co LP | 5.24M | 3.05% | +706.34% | Jun 2026 |
| Geode Capital Management, LLC | 3.58M | 2.09% | +7.18% | Jun 2026 |
| Woodline Partners LP | 2.70M | 1.57% | -18.17% | Jun 2026 |
| Siren, L.L.C. | 2.47M | 1.44% | +37.49% | Jun 2026 |
| Bvf Inc | 2.36M | 1.38% | 0.00% | Jun 2026 |
| Gem Investment Advisors, LLC | 2.17M | 1.27% | 0.00% | Jun 2026 |
| Baker Bros Advisors LP | 2.13M | 1.24% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.73M | 1.01% | +192.76% | Jun 2026 |
| Nuveen, LLC | 1.72M | 1.00% | +403.07% | Jun 2026 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 1.60M | 0.93% | 0.00% | Jun 2026 |
Absci Corp company profile
- Company name
- Absci Corp
- Ticker
- ABSI.US
- Exchange
- USA Stocks
- Listed since
- Jul 22, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 140
- Fiscal year end
- December
- Address
- 18105 SE Mill Plain Boulevard, Vancouver, WA, United States, 98683
- Phone
- 360 949 1041
- Website
- absci.com
About Absci Corp
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Absci Corp management
10- Mr. Sean McClainFounder, CEO, President & Director · born 1990
- Dr. Zachariah Jonasson Ph.D.Chief Business Officer & CFO · born 1973
- Mr. Todd Bedrick CPASenior VP & Chief Accounting Officer
- Mr. Alexander Khan CPACVP of Finance & Head of Investor Relations
- Ms. Shelby Walker J.D.Chief Legal Officer · born 1975
- Ms. Jeanne Schreuder M.B.A., SPHRSenior Vice President of People & Experience
- Mr. Wen ShaChief of Staff
- Dr. Christine Lemke D.V.M., M.B.A., Ph.D.Senior Vice President of Portfolio & Growth Strategy
- Dr. Ransi Somaratne FACC, M.B.A., M.D.Chief Medical Officer · born 1966
- Dr. Moetaz B. Albizem M.D.Senior Vice President of Clinical Operations